Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
China Export Growth Surges in April as Global Buyers Rush to Secure Supplies 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Oil Prices Rise Amid Strait of Hormuz Tensions and U.S.-Iran Ceasefire Uncertainty 
Asian Currencies Slip as US Dollar Gains on Rising Iran Tensions and Awaited Jobs Data 
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income 
Iran-U.S. Peace Deal Near as Oil Prices Fall and Nuclear Disputes Persist 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
Armani Group Eyes Strategic Stake Sale to Luxury Giants 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Sony Forecasts Lower 2027 Profit Despite Strong Music and Sensor Growth 
Dollar Struggles to Rally Despite Strong US Data as Fed Hike Expectations Remain Limited 
Gold Prices Hold Firm as Iran Tensions and Dollar Swings Drive Safe-Haven Demand 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Dollar Slips as Strong U.S. Jobs Data Reduces Fed Rate Cut Expectations 
Wall Street Futures Edge Higher as Iran Tensions and AI Optimism Shape Markets 
Philips announced that it has started the repairs and replacements of its first-generation respiratory devices that were recalled in the United States. The healthcare unit of the Dutch multinational conglomerate will be addressing the issues in the recalled DreamStation devices numbering to millions.
Based on the recall notice, it was stated that the recalled machines pose potential health risks so customers were immediately told to stop using the affected model units of Philip’s respiratory machines. As Reuters reported, the U.S. Food and Drug Administration (FDA) announced a recall on some models of DreamStation respiratory and ventilator devices in June.
They were found to have become toxic over time as the foam part might deteriorate. When this happens, the machines may potentially cause cancer. Philips received authorization from the FDA to allow rework in the affected units that could reach four million in total.
Almost half of the affected respiratory machines were sold in the U.S. so the latest recall notification is for this country only at this time. For the rest of the world, Philips has issued a field safety notice for the issue which the FDA classified as Class I recall. In any case, the company said that it will take them about a year to replace or repair the machines.
“We fully recognize that the timeframe for remediation of the affected devices places patients in a difficult situation,” Royal Philips’ chief executive officer, Frans van Houten, said in a press release. “We are mobilized to deliver a solution to them as fast as possible. We have significantly increased our production, service and rework capacity, and further intensified our outreach to our customers and their patients.”
The CEO is also urging patients who are using the affected devices to register their units on the website dedicated for the recalls. This will help them with the process of tracking and obtaining details about the machines.
Aside from the ongoing repairs and replacements, Philips continues to communicate with the FDA to address any other details of the recall as well as mitigation plans in the country. The company has reserved $590 million for the recall operation this year.
